These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 34835485)

  • 21. Genetic and structural identification of an O-acyltransferase gene (oacC) responsible for the 3/4-O-acetylation on rhamnose III in Shigella flexneri serotype 6.
    Knirel YA; Wang J; Luo X; Senchenkova SN; Lan R; Shpirt AM; Du P; Shashkov AS; Zhang N; Xu J; Sun Q
    BMC Microbiol; 2014 Oct; 14():266. PubMed ID: 25327486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. From an in vivo to an in vitro relative potency (IVRP) assay to fully characterize a multicomponent O-antigen based vaccine against Shigella.
    Necchi F; Giannelli C; Acquaviva A; Alfini R; Monaci V; Arato V; Rossi O; Micoli F
    Carbohydr Polym; 2023 Aug; 314():120920. PubMed ID: 37173008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An attenuated Shigella mutant lacking the RNA-binding protein Hfq provides cross-protection against Shigella strains of broad serotype.
    Mitobe J; Sinha R; Mitra S; Nag D; Saito N; Shimuta K; Koizumi N; Koley H
    PLoS Negl Trop Dis; 2017 Jul; 11(7):e0005728. PubMed ID: 28727722
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative proteomic analysis of Shigella flexneri and Shigella sonnei Generalized Modules for Membrane Antigens (GMMA) reveals highly pure preparations.
    Maggiore L; Yu L; Omasits U; Rossi O; Dougan G; Thomson NR; Saul A; Choudhary JS; Gerke C
    Int J Med Microbiol; 2016 Feb; 306(2):99-108. PubMed ID: 26746581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaccination with Shigella flexneri 2a conjugate induces type 2a and cross-reactive type 6 antibodies in humans but not in mice.
    Farzam N; Ramon-Saraf R; Banet-Levi Y; Lerner-Geva L; Ashkenazi S; Kubler-Kielb J; Vinogradov E; Robbins JB; Schneerson R
    Vaccine; 2017 Sep; 35(37):4990-4996. PubMed ID: 28797729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of O-Antigen Chain Length Regulation on the Immunogenicity of
    Gasperini G; Raso MM; Arato V; Aruta MG; Cescutti P; Necchi F; Micoli F
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33525644
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A similarity in the O-acetylation pattern of the O-antigens of Shigellaflexneri types 1a, 1b, and 2a.
    Perepelov AV; L'vov VL; Liu B; Senchenkova SN; Shekht ME; Shashkov AS; Feng L; Aparin PG; Wang L; Knirel YA
    Carbohydr Res; 2009 Mar; 344(5):687-92. PubMed ID: 19246033
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison and Optimization of Quantification Methods for
    Raso MM; Vassallo O; Micoli F; Giannelli C
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830042
    [No Abstract]   [Full Text] [Related]  

  • 29. Quantitative analysis of IgG class and subclass and IgA serum response to Shigella sonnei and Shigella flexneri 2a polysaccharides following vaccination with Shigella conjugate vaccines.
    Robin G; Keisari Y; Slepon R; Ashkenazi S; Cohen D
    Vaccine; 1999 Aug; 17(23-24):3109-15. PubMed ID: 10462247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serotype-converting bacteriophage SfII encodes an acyltransferase protein that mediates 6-O-acetylation of GlcNAc in Shigella flexneri O-antigens, conferring on the host a novel O-antigen epitope.
    Sun Q; Knirel YA; Wang J; Luo X; Senchenkova SN; Lan R; Shashkov AS; Xu J
    J Bacteriol; 2014 Oct; 196(20):3656-66. PubMed ID: 25112477
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acetylation of O-specific lipopolysaccharides from Shigella flexneri 3a and 2a occurs in Escherichia coli K-12 carrying cloned S. flexneri 3a and 2a rfb genes.
    Yao Z; Liu H; Valvano MA
    J Bacteriol; 1992 Dec; 174(23):7500-8. PubMed ID: 1280255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bacteriophage Sf6 host range mutant that infects Shigella flexneri serotype 2a2 strains.
    Teh MY; Tran ENH; Morona R
    FEMS Microbiol Lett; 2022 Apr; 369(1):. PubMed ID: 35218200
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Shigella flexneri O-antigen epitopes: chemical and immunochemical analyses reveal that epitopes of type III and group 6 antigens are identical.
    Carlin NI; Wehler T; Lindberg AA
    Infect Immun; 1986 Jul; 53(1):110-5. PubMed ID: 2424840
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibodies Elicited by the
    Micoli F; Rossi O; Conti V; Launay O; Sciré AS; Aruta MG; Nakakana UN; Marchetti E; Rappuoli R; Saul A; Martin LB; Necchi F; Podda A
    Front Immunol; 2021; 12():671325. PubMed ID: 34017343
    [No Abstract]   [Full Text] [Related]  

  • 35. Characterization and immunogenicity of a Shigella flexneri 2a O-antigen bioconjugate vaccine candidate.
    Ravenscroft N; Braun M; Schneider J; Dreyer AM; Wetter M; Haeuptle MA; Kemmler S; Steffen M; Sirena D; Herwig S; Carranza P; Jones C; Pollard AJ; Wacker M; Kowarik M
    Glycobiology; 2019 Aug; 29(9):669-680. PubMed ID: 31206156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. O-Acetylation in the O-specific polysaccharide isolated from Shigella flexneri serotype 2a.
    Kubler-Kielb J; Vinogradov E; Chu C; Schneerson R
    Carbohydr Res; 2007 Feb; 342(3-4):643-7. PubMed ID: 17087926
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Sadredinamin M; Yazdansetad S; Alebouyeh M; Yazdi MMK; Ghalavand Z
    Oman Med J; 2023 Jul; 38(4):e522. PubMed ID: 37724320
    [No Abstract]   [Full Text] [Related]  

  • 38. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies.
    Kotloff KL; Winickoff JP; Ivanoff B; Clemens JD; Swerdlow DL; Sansonetti PJ; Adak GK; Levine MM
    Bull World Health Organ; 1999; 77(8):651-66. PubMed ID: 10516787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development, Interlaboratory Evaluations, and Application of a Simple, High-Throughput
    Nahm MH; Yu J; Weerts HP; Wenzel H; Tamilselvi CS; Chandrasekaran L; Pasetti MF; Mani S; Kaminski RW
    mSphere; 2018 Jun; 3(3):. PubMed ID: 29898979
    [No Abstract]   [Full Text] [Related]  

  • 40. Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in Europe.
    Launay O; Lewis DJM; Anemona A; Loulergue P; Leahy J; Sciré AS; Maugard A; Marchetti E; Zancan S; Huo Z; Rondini S; Marhaba R; Finco O; Martin LB; Auerbach J; Cohen D; Saul A; Gerke C; Podda A
    EBioMedicine; 2017 Aug; 22():164-172. PubMed ID: 28735965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.